Abstracts

Dynamic Changes of CXCL10 Isoforms and DPP4 During IFN-Free Treatment for HCV

Background: The intrahepatic endogenous interferon response fails to promote hepatitis C virus (HCV) clearance once chronic infection is established. The interferon (IFN)-stimulated chemokine CXCL10 (IP-10) is hepatically produced in chronic infection. A short CXCL10 isoform with antagonistic properties is generated by DPP4 activity, and likely contributes to impaired immunity in chronic HCV infection. We previously…

Mx1 and OAS1-2 SNPs Are Related With Severity of Liver Disease in HIV/HCV Coinfection

Background: The innate immune response against viruses induces production of interferon (IFN) type I (alpha, beta) and type III (gamma), which in turn induces the expression of genes encoding various proteins with antiviral activity, including the myxovirus resistance protein (Mx) and the family of 2′-5′-oligoadenylate synthetase (OAS) enzymes. These proteins have been linked to the…

Treatment With DCV Plus ASV Reduces Immune Activation in HIV/HCV Coinfected Patients

Background: HIV/HCV co-infected subjects have higher levels of immune activation and are traditionally more difficult to treat with immune-based therapy for HCV compared to those with HCV mono-infection. Directly-acting antivirals have shown promising results in treating subjects with HCV mono-infection in the absence of interferon and ribavirin. Here we describe changes in immune activation associated…

A Novel Mechanism of Resistance to Multiple bNAbs Revealed by Natural Variation in Panel of 199 HCVpp

Background: Broadly-neutralizing monoclonal antibodies (bNAbs) are informative for vaccine development for highly variable viruses including hepatitis C virus (HCV). However, HCV resistance to bNAbs is poorly understood, in part due to a lack of neutralization testing using diverse panels of HCV variants. HC33.4 and AR4A are two of the most potent bNAbs characterized to date,…

Structural Basis of Inhibition and Resistance Mechanism to EFdA, a Highly Potent NRTI

Background: Unlike any current clinical nucleoside reverse transcriptase inhibitors (NRTIs), 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) retains a 3′-OH. EFdA has exceptional potency in vivo and in vitro, highly efficient against drug-resistant strains and has outstanding specificity index. EFdA can act as an immediate or as a delayed chain terminator, by affecting translocation of RT after its incorporation in…

Structural Basis and Distal Effects of Gag Substrate Coevolution in Drug Resistance to HIV-1 Protease

Background: HIV-1 protease is a key antiviral drug target due to its essential function of processing viral polyproteins. Among primary protease mutations, I50V is commonly observed in patients failing therapy with PIs APV and DRV. In addition to conferring resistance to PIs, I50V mutation also impairs substrate processing. Mutations in the p1-p6 cleavage site are…